Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVE: Dostarlimab +/- Bevacizumab vs Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma
NCT06023862Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of dostarlimab in clear cell carcinoma (CCC), sponsored by Yonsei University. Started Jan 2024; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
clear cell carcinoma (CCC)
Beyond the preview
Go deeper on NCT06023862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023862.